2016 / 04

Next Paper
DOI: 10.24075/brsmu.2016-04-06

OPINION

Nuclear medicine imaging in dementia

Kondakov AK1,3, Znamensky IA1,2,3, Mosin DYu2,3, Grechko AV2
About authors

1 Department of Radiology, Biomedical Faculty,
Pirogov Russian National Research Medical University, Moscow, Russia

2 Hospital for incurable patients – the Scientific Medical and Rehabilitation Center, Moscow, Russia

3 Department of Radionuclide Imaging,
Central Clinical Hospital of the Russian Academy of Sciences, Moscow, Russia

Correspondence should be addressed: Anton Kondakov
Litovsky bulvar, d. 1a, Moscow, Russia, 117593; moc.liamg@k.a.vokadnok

Received: 2016-08-16 Accepted: 2016-08-21 Published online: 2017-01-05
|
  1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 2013 Jan; 9 (1): 63–75.e2. DOI: 10.1016/j.jalz.2012.11.007.
  2. Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET and SPECT in Neurology. Berlin, Heidelberg: Springer-Verlag; 2014.
  3. Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM. Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography. Psychiatry Clin Neurosci. 2005 Jun; 59 (3): 280–90. DOI: 10.1111/j.1440-1819.2005.01372.x.
  4. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004 Nov–Dec; 12 (6): 554–70. DOI: 10.1176/appi.ajgp.12.6.554.
  5. Yeo JM, Lim X, Khan Z, Pal S. Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci. 2013 Oct; 263 (7): 539–52. DOI: 10.1007/s00406-013-0426-z.
  6. Efimova NYu, Chernov VI, Efimova IYu, Shnaider OL, Popov SV. Vliyanie implantatsii elektrokardiostimulyatora na kognitivnuyu disfunktsiyu u patsientov s postoyannoi formoi fibrillyatsii predserdii: vzaimosvyaz' s tserebral'noi perfuziei. Vestnik aritmologii. 2008; (54): 15–9. Russian.
  7. Murashko NK. Odnofotonnaya emissionnaya tomografiya pri khronicheskoi gipertonicheskoi entsefalopatii. Klinicheskaya gerontologiya. 2007; (8): 26–9. Russian.
  8. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med. 2002 Aug; 43 (8): 983–90.
  9. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage. 2003 Nov; 20 (3): 1894–8.
  10. Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O'Brien JT, Fox NC, et al. Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry. 2014 Dec; 85 (12): 1426–34. DOI: 10.1136/jnnp-2014-307662.
  11. Davison CM, O'Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: A systematic review. Int J Geriatr Psychiatry. 2014 Jun; 29 (6): 551–61. DOI: 10.1002/gps.4036.
  12. Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev. 2016 Feb 11. DOI: 10.1016/j.arr.2016.02.003. [Epub ahead of print].
  13. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004 Mar; 55 (3): 306–19. DOI: 10.1002/ana.20009.
  14. Villemagne VL. Amyloid imaging: Past, present and future perspectives. Ageing Res Rev. 2016 Jan 28. DOI: 10.1016/j.arr.2016.01.005. [Epub ahead of print].
  15. Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. J Neuroimaging. 2012 Jul; 22 (3): 225–30. DOI: 10.1111/j.1552-6569.2011.00583.x.
  16. Baglio F, Preti MG, Farina E. Neuroimaging Findings in Dementia with Lewy Body: A Review. In: Bright P, editor. Neuroimaging — Methods. InTech; 2012. DOI: 10.5772/24221. Available from: http://www.intechopen.com/books/neuroimaging-methods/neuroimaging-findings-in-dementia-with-lewy-body-a-review-
  17. Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. Br J Psychiatry. 2015 Feb; 206 (2): 145–52. DOI: 10.1192/bjp.bp.114.148643.
  18. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009 Jan 6; 72 (1): 56–62. DOI: 10.1212/01.wnl.0000338622.27876.0d.
  19. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2012 Jun; 39 (6): 990–1000. DOI: 10.1007/s00259-012-2102-3.